Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease

Hormone and Metabolic Research

Volumn 37, Issue 12, 2005, Pages 741-744

  Schott, Matthias ^a   Minich, W B ^c   Willenberg, H S ^a   Papewalis, C ^a   Seissler, J ^b   Feldkamp, J ^d   Bergmann, A ^c   Scherbaum, W A ^a   Morgenthaler, N G ^c  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c BRAHMS AG   (Germany)

^d OWL University   (Germany)

Author keywords

Blocking autoantibodies; Graves' disease; Relapse; Remission; Stimulating autoantibodies; TSH receptor antibodies

Indexed keywords

AUTOANTIBODY; THYROTROPIN RECEPTOR;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BIOASSAY; CHO CELL; FEMALE; FOLLOW UP; GRAVES DISEASE; HUMAN; INFORMATION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OUTPATIENT; OUTPATIENT DEPARTMENT; PATIENT; PREDICTION; PREGNANCY; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BLOCKING; RELAPSE; REMISSION;

ADOLESCENT; ADULT; AUTOANTIBODIES; BIOLOGICAL ASSAY; CHI-SQUARE DISTRIBUTION; FEMALE; FOLLOW-UP STUDIES; GRAVES DISEASE; HUMANS; IMMUNOGLOBULINS, THYROID-STIMULATING; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECEPTORS, THYROTROPIN; RECURRENCE; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 29744460733     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-921099     Document Type: Article

References (31)

1. Weetman AP. Graves' disease. N Engl J Med 2000; 343: 1236-1248
2. Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev 1998; 19: 673-716
3. Morgenthaler NG. New assay systems for thyrotropin receptor antibodies. Curr Opin Endocrinol Diabetes 1999; 6: 251-260
4. Smith BR, Hall R. Thyroid-stimulating immunoglobulins in Graves' disease. Lancet 1974; 2: 427-431
5. Costagliola S, Morgenthaler NG, Hoermann R, Badenhoop K, Struck J, Freitag D et al. Second generation assay for thyrotropin receptor anti-bodies has superior diagnostic sensitivity for Graves' disease. J Clin Endocrinol Metab 1999; 84: 90-97
6. Schott M, Feldkamp J, Bathan C, Fritzen R, Scherbaum WA, Seissler J. Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical evaluation. Horm Metab Res 2000; 32: 429-435
7. Massart C, Orgiazzi J, Maugendre D. Clinical validity of a new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves' disease treated with antithyroid drugs. Clin Chim Acta 2001; 304: 39-47
8. Maugendre D, Massart C. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay. Clin Endocrinol (Oxf) 2001; 54: 89-96
9. Giovanella L, Ceriani L, Garancini S. Clinical applications of the 2nd generation assay for anti-TSH receptor antibodies in Graves' disease. Evaluation in patients with negative 1st generation test. Clin Chem Lab Med 2001; 39:25-28
10. Zimmermann-Belsing T, Nygaard B, Rasmussen AK, Feidt-Rasmussen U. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease. Eur J Endocrinol 2002; 146: 173-177
11. Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin Endocrinol (Oxf) 2001; 55: 381-390
12. Wallaschofski H, Orda C, Georgi P, Miehle K, Paschke R. Distinction between autoimmune and non-autoimmune hyperthyroidism by determination of TSH-receptor antibodies in patients with the initial diagnosis of toxic multinodular goiter. Horm Metab Res 2001; 33: 504-507
13. Morgenthaler NG, Nagata A, Katayama S, Bergmann A, Iitaka M. Detection of low titre TBII in patients with Graves' disease using recombinant human TSH receptor. Clin Endocrinol (Oxf) 2002; 57: 193-198
14. Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K et al. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol (Copenh) 1989; 120: 689-701
15. Feldt-Rasmussen U, Schleusener H, Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab 1994; 78: 98-102
16. Davies TF, Roti E, Braverman LE, DeGroot LJ. Thyroid controversy- stimulating antibodies. J Clin Endocrinol Metab 1998; 83 (11): 3777-3785
17. Wallaschofski H, Miehle K, Mayer A, Tuschy U, Hentschel B, Paschke R. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment. Horm Metab Res 2002; 34: 383-388
18. Morgenthaler NG, Pampel I, Aust G, Seissler J, Scherbaum WA. Application of a bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor. Horm Metab Res 1998; 30: 162-168
19. Lenzner C, Morgenthaler NG. The effect of thyrotropin-receptor blocking antibodies on stimulating autoantibodies from patients with Graves'disease. Thyroid 2003; 13: 1153-1161
20. Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Willenberg HS, Scherbaum WA et al. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease. Horm Metab Res 2004; 36: 92-96
21. Quadbeck B, Hoermann B, Roggenbuck U, Hahn S, Mann K, Janssen OE. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in graves' disease. Thyroid 2005; 15: 1047-1054
22. Morgenthaler NG, Minich WB, Willnich M, Bogusch T, Hollidt JM, Weglohner W et al. Affinity purification and diagnostic use of TSH receptor autoantibodies from human serum. Mol Cell Endocrinol 2003; 212: 73-79
23. Schott M, Scherbaum WA, Morgenthaler NG. TSH-receptor autoanti-bodies in Graves' disease: recent developments in the diagnosis and therapy monitoring. Trends Endocrinol Metab 2005; 16: 243-248
24. McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996; 334: 220-224
25. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997; 7: 369-375
26. Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid 1998; 8: 119-124
27. Kasagi K, Konishi J, Iida Y, Ikekubo K, Mori T, Kuma K et al. A new in vitro assay for human thyroid stimulator using cultured thyroid cells: effect of sodium chloride on adenosine 3′,5′-monophosphate increase. J Clin Endocrinol Metab 1982; 54: 108-114
28. Wallaschofski H, Paschke R. Detection of thyroid stimulating (TSAB)-and thyrotropin stimulation blocking (TSBAB) antibodies with CHO cell lines expressing different TSH-receptor numbers. Clin Endocrinol (Oxf) 1999; 50: 365-372
29. Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y et al. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990;70:675-679
30. Garcia-Mayor RV, Paramo C, Luna CR, Perez Mendez LF, Galofre JC, Andrade A. Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J Endocrinol Invest 1992; 15: 815-820
31. Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Yet al. Antithyroid drugs and Graves' disease - prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf) 1999; 50: 127-132